TVM Capital Life Science

Hubert Birner is featured in the 2024 EY German Biotechnology Report! His article, "Investor’s insight into AI in biotech: faster analytics and lower costs drive growth," explores how AI is transforming the biopharma industry. 🔬 AI is revolutionizing drug discovery, medical imaging and predictive modeling, accelerating growth and reducing costs. Hubert highlights AI's potential and the challenges in its integration. 📊 Highlights: AI's role in drug target identification, screening and predictive modeling. Success stories from AI-driven companies like Exscientia, Genesis Therapeutics, Vektor Medical, Inc., Smart Reporting GmbH and BioNTech SE. The importance of digital transformation and ethical considerations in AI application. 🌍 Global Impact: AI is making significant strides in life science innovation globally. Despite different adoption rates, high-quality data and expertise are universally needed. TVM invests in companies were AI drives core product development, combining AI's power with human expertise for responsible advancements. Read more about Hubert's insights and the future of AI in biopharma in the latest EY Biotech report: https://lnkd.in/eiAP4-Jj #AI #Biopharma #Innovation #Biotechnology #LifeSciences #Investment #VC #EYBiotechReport2024

🧬 Honored to return to BIOTECH AUSTRIA, the emerging platform for the local biotech industry, and proud to contribute to its ongoing success. Congratulations to the organizers for the incredible progress made in just two years! 🧬 With over 250 participants from 13 countries, this year’s summit in Innsbruck not only solidified its role as a key event for the Austrian biotech scene but also fostered high-level yet personal exchanges among leading investors, scientists, and start-ups. TVM Capital Life Science looks forward to continuing the conversation next October 2025 in Graz! Check out transkript's recap of the second Biotech Summit Austria and the exciting discussions it sparked across the industry. https://lnkd.in/d7C5Pymu #BiotechAustria #Innovation #LifeSciences #Collaboration

🚀 Perspectives on the German Biotech Funding landscape 🚀   In his recent article, TVM Capital Life Sciences' Managing Partner, Hubert Birner, highlights the resilience of the German biotech sector amidst challenging times. While the past few years have tested the industry with economic and geopolitical headwinds, 2024 is showing signs of a positive shift when it comes to accessing capital.   Key takeaways: 💼 Capital is on the Rise: German biotech firms raised €1.1B in 2023—an increase from 2022—with early 2024 already seeing nearly €500M in private investments. 🌍 Global Interest: Many German companies have successfully attracted significant foreign investments, underscoring their global competitiveness. 🤝 Opportunities & Challenges: Despite encouraging trends, challenges remain, including a decline in new company formations and early-stage funding.   Hubert calls for continued collaboration to ensure Germany remains an attractive hub for biotech innovation.   Read the full article in German here: https://lnkd.in/gbY3sPkJ   #biotechnology #lifeSciences #innovation #investment #GermanBiotech #TVM  

🔍 Medtech at a Turning Point 🔍 TVM Capital Life Science’s Managing Partner, Dr. Luc Marengere, recently shared insights with Shani Alexander of BioWorld MedTech at LSI Europe '24 on the state of the medtech sector—medtech is indeed at a pivotal moment. 💬 "The entire ecosystem is coming together. It’s not just about technologies; you need investors and buyers creating a healthier, more viable industry. Now, we’re seeing companies valued at biotech levels and exciting opportunities for investment," says Luc. With over $900M under management, TVM is proud to support companies transforming patient care and medtech innovation. Notable investments, such as TVM’s support of Access Vascular, Inc. CSA Medical Inc, Kent Imaging and Vektor Medical, Inc. Medical reflect our commitment to fostering solutions that deliver tangible patient outcomes and redefine treatment pathways. As Luc notes, these are "truly transformational opportunities"—and the future is bright for medtech. Read the full article here (pay wall): https://lnkd.in/eWMrydRb #MedTech #HealthcareInnovation #VentureCapital #LifeSciences #MedTechDeals #InvestmentOpportunities

🌟 What an incredible week at LSI Europe ‘24! 🌍✨ TVM Capital Life Sciences had the privilege of engaging in numerous productive meetings, gaining valuable insights into the rapidly evolving medtech landscape, and connecting with forward-thinking leaders and innovators, as well as co-investors. Our Managing Partner, Dr. Luc Marengere Marengère, took the stage, discussing cross-border investing in medtech—shedding light on how collaboration across borders can drive growth and innovation in the sector. It was an inspiring conversation on the critical importance of syndicating investments to unlock new opportunities globally. We also celebrated our portfolio companies Vektor Medical, Inc. (Robert J. Krummen) and Kent Imaging (Pierre Lemire) — both of which have made great progress this year, with exciting milestones expected ahead. As always, TVM remains committed to making investments to transform healthcare. Thank you to everyone who met with us, shared their insights, and contributed to a truly transformative summit! Looking forward to continued collaboration and innovation. #LSIEurope24 #MedTech #HealthcareInnovation #HealthTech #InvestmentStrategy #CrossBorderInvesting #Innovation #VC

🚀 Managing Partner, Hubert Birner, will represent TVM Capital Life Science at the 24th Annual Biotech in Europe Forum (#Sachs_BEF), September 25-26, 2024, at the Mövenpick Hotel in Basel. This prestigious event, part of the Sachs Autumn Life Sciences Week (#SALSW), brings together thought leaders from across the biotech and life sciences sectors to address the key investment challenges for 2024, explore strategic partnerships and discuss future industry trends. Hubert will share his insights during the forum's high-level panels, where he will offer perspectives on the evolving landscape of biopharma investment and innovation, particularly around early-stage ventures. Join TVM for two days of impactful discussions, a global company showcase and valuable networking opportunities with over 600+ delegates from leading investors, public and private companies, and the pharma industry. #LifeSciences #Biotech #HealthTech #Investment #Innovation #Partnerships

🌍✨ TVM Capital Life Science is excited to announce our participation in the LSI Europe ’24 Emerging Medtech Summit being held September 16-20, 2024, in Sintra, Portugal! 🚀 Alongside supporting our portfolio companies Vektor Medical, Inc. and Kent Imaging, TVM is on the lookout for transformative partnerships and medtech innovations that are reshaping the future of healthcare. As Dr. Luc Marengere Marengère stated, “Medtech innovation continues to drive transformative changes in patient care, operational efficiency, and cost reduction. We look forward to engaging with fellow industry leaders at this year’s Summit to explore new opportunities that align with our investment strategy.” Hubert Birner added, “The rapid advancements in medtech create unprecedented opportunities to address unmet clinical needs. TVM is dedicated to supporting visionary companies that are pioneering healthcare solutions.” Join us at Penha Longa, The Ritz-Carlton to connect, collaborate and explore the future of medtech! #LSIEurope24 #MedTech #HealthcareInnovation #HealthTech #Innovation

TVM portfolio company, Egg Medical, is making a major impact in protecting interventional teams with its game-changing EggNest Complete Radiation Protection System. We are inspired by the story of Dean Kereiakes, MD, FACC, MSCAI to make occupational health and safety a priority for all interventional healthcare workers. “We are proud to be involved with Egg Medical as their transformational product protects all healthcare professionals doing life saving work in the cath labs,” says TVM's Marc Rivière, MD, General Partner and Fund Chief Medical Officer.

🎉 Congratulations to leon-nanodrugs on their successful Series D financing round! 🎉   TVM Capital Life Science is proud to continue supporting LEON as they drive innovation in the Cell & Gene Therapy space with their cutting-edge nanoencapsulation technology. This new investment is a significant milestone that will enable LEON to expand their product portfolio and to select the best possible strategic partner to bring their groundbreaking solutions to the market. With this momentum, TVM is excited to see LEON's continued growth and the positive impact their technology will have on bringing novel treatments to patients.    #LifeScience #Biotech #Innovation #CellAndGeneTherapy #Nanotechnology #HealthcareInnovation #VC

🌟Biotech Finance Summit🌟 Stefan Fischer, Managing Partner (Finance) at TVM Capital Life Science, participated in a panel discussion at the Biotech Finance Summit 2024 in Berlin yesterday. Since 2007, BIO Deutschland e. V. has hosted this Summit as a specialized platform for exchange and information on finance topics. This event targets CFOs, CEOs and heads of corporate finance and accounting from biotechnology companies. With around 90 participants, this year's event offered ample opportunities for discussions and networking around finance. Stefan was part of a distinguished panel moderated by Prof. Dr. Dirk Honold from Technische Hochschule Nürnberg, alongside Dr. Klaus Maleck, ITM and Prof. Dr. Luise Hölscher, Federal Ministry of Finance. #BiotechFinanzGipfel2024 #Biotech #Finance #Networking #Leadership #Innovation